2. Academic Validation
  3. Identification and experimental validation of Stearoyl-CoA desaturase is a new drug therapeutic target for osteosarcoma

Identification and experimental validation of Stearoyl-CoA desaturase is a new drug therapeutic target for osteosarcoma

  • Eur J Pharmacol. 2023 Dec 7:176249. doi: 10.1016/j.ejphar.2023.176249.
Jiangbo Nie 1,  Cheng He 2,  Zhiguo Shu 1,  Ning Liu 1,  Yanxin Zhong 1,  Xinhua Long 3,  Jiaming Liu 1,  Feng Yang 1,  Zhili Liu 4,  Ping Huang 5
Affiliations

Affiliations

  • 1 Department of Orthopedic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China; Institute of Spine and Spinal Cord, Nanchang University, Nanchang, China; Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • 2 Department of Orthopedics, The 908th Hospital of Joint Logistics Support Forces of Chinese PLA, Nanchang, China.
  • 3 Institute of Spine and Spinal Cord, Nanchang University, Nanchang, China; Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • 4 Department of Orthopedic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China; Institute of Spine and Spinal Cord, Nanchang University, Nanchang, China; Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China. Electronic address: zhili-liu@ncu.edu.cn.
  • 5 Institute of Spine and Spinal Cord, Nanchang University, Nanchang, China; Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China; Department of Nutrition, The First Affiliated Hospital of Nanchang University, Nanchang, China. Electronic address: ndyfy03260@ncu.edu.cn.
PMID: 38070637 DOI: 10.1016/j.ejphar.2023.176249
Abstract

Osteosarcoma (OS) is the most common malignant bone tumor. Fatty acid reprogramming plays an essential role in OS progression. However, new fatty acid related therapeutic targets of OS have not been completely elucidated. Therefore, we firstly identified 113 differentially expressed fatty acid metabolism genes using bioinformatic analysis, 19 of which were found to be associated with OS prognosis. Then, 7 hub genes were screened out and yielded a strong prediction accuracy (AUC value = 0.88, at 3 years) for predicting the survival status of OS patients. Furthermore, we confirmed that SCD was highly expressed in OS cells and patients. And Knock-down of SCD impaired proliferation and migration of OS cells. Moreover, SCD was transcriptionally activated by c-Myc to promote proliferation and migration of OS cells. Finally, SCD inhibitor could significantly induce OS Ferroptosis in vitro and in vivo. In conclusion, we identified that SCD was a reliable risk factor for OS patients. And SCD was activated by c-Myc. The inhibitor of SCD could significantly impaired OS growth and induce OS Ferroptosis, which indicated that SCD was a potential drug target for OS treatment.

Keywords

Drug therapeutic target; Fatty acid metabolism; Osteosarcoma; SCD; c-Myc.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z